[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630472":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":21,"centralContacts":22,"locations":28,"responsibleParty":47,"collaborators":21,"id":49,"slug":21,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":21,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":21,"overallStatus":31,"whyStopped":21,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"patients with Autoimmune encephalitis","EXPERIMENTAL",[12],"Other: TEP with radioligand EAI 714",{"label":14,"type":10,"description":14,"interventionNames":15},"control",[12],[17],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"TEP with radioligand EAI 714","60-minutes \\[18F\\]-DPA-714 PET imaging",[14,9],null,[23],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},"Marie Rafiq, MD","CONTACT","+33 561779491","rafiq.m@chu-toulouse.fr",[29],{"facility":30,"status":31,"city":32,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"University Hospital","RECRUITING","Toulouse","France","FR",{"type":36,"coordinates":37},"Point",[38,39],1.44367,43.60426,{"lat":39,"lon":38},[42,44],{"name":43,"role":25,"phone":21,"phoneExt":21,"email":27},"Marie RAFIQ, MD",{"name":45,"role":46,"phone":21,"phoneExt":21,"email":21},"Marie rafiq, MD","PRINCIPAL_INVESTIGATOR",{"type":48,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100630472",false,"NCT07488117","Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?","EAI-714","Inclusion Criteria:\n\n* Age 18-80 years;\n* meeting clinical criteria for \"possible\" AE with identified antibodies;\n* newly diagnosed with symptoms \\\u003C6 months;\n* no second-line immunosuppressive treatment;\n* high or mixed TSPO binding affinity phenotype.\n\nExclusion Criteria:\n\n* Pregnant women;\n* contraindications to MRI;\n* known allergic reaction to \\[18F\\]-DPA-714; legal protection measure;\n* paraneoplastic syndrome following immune checkpoint inhibitor therapy.",true,"ALL","18 Years","80 Years",{"count":60,"type":61},40,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","This study aims to evaluate the effectiveness of \\[18F\\]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE). The primary objective is to compare \\[18F\\]-DPA-714 binding in AE patients to healthy controls.",[67],"Autoimmune Encephalitis (AE)","2026-05-06",{"date":70,"type":71},"2026-05-11","ACTUAL",{"date":73,"type":71},"2026-03-31",{"date":75,"type":61},"2028-01",{"name":5,"class":6},1]